版本:
中国

BRIEF-Rigel restructures to focus on Fostamatinib commercialization

Sept 15 Rigel Pharmaceuticals Inc

* Rigel restructures to focus on fostamatinib commercialization

* Rigel Pharmaceuticals Inc says plans to build a commercial organization to support potential launch of fostamatinib

* Says rigel has reduced its workforce by 38%, resulting in elimination of 46 positions

* Reduction and refocus is expected to provide approximately $17-20 million in savings annually going forward

* Still assessing full charges associated with measure including about $5.7 million in cash-related restructuring expenses

* Says workforce reduction mostly in research area

* Says cash-related restructuring expenses are expected to be recorded predominantly in Q3 of 2016.

* Donald Payana has retired from board and from position as executive vice president and president of discovery and research Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐